May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab
M. Ren; R.P. A. Manzano; G.A. Peyman; P. Khan; P. Carvounis; M. Kivilcim
Author Affiliations & Notes
  • M. Ren
    Ophthalmology, Tulane, New Orleans, LA
  • R.P. A. Manzano
    Ophthalmology, Tulane, New Orleans, LA
  • G.A. Peyman
    Ophthalmology, Tulane, New Orleans, LA
  • P. Khan
    Ophthalmology, Tulane, New Orleans, LA
  • P. Carvounis
    Ophthalmology, Baylor, Houston, TX
  • M. Kivilcim
    Ophthalmology, Tulane, New Orleans, LA
  • Footnotes
    Commercial Relationships  M. Ren, None; R.P.A. Manzano, None; G.A. Peyman, None; P. Khan, None; P. Carvounis, None; M. Kivilcim, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1638. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      M. Ren, R.P. A. Manzano, G.A. Peyman, P. Khan, P. Carvounis, M. Kivilcim; Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1638.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularization in rats.

Methods: : Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) was used to perform chemical cauterization of the cornea of 16 eyes of 16 male Long–Evans (LE) rats. For the following 7 days, the 10 eyes in the treatment group received twice daily instillation of Bevacizumab 4mg/ml drops while the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analyzed to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.

Results: : In the Bevacizumab treated eyes, neovascularization covered, on average, 38.2 ± 15.5% (mean ± standard deviation[SD]) of the corneal surface compared with 63.5 ± 5.0% (mean ± SD) in the control group (p=0.0005, Student’s t–test).

Conclusions: : Topically administered Bevacizumab (Avastin) at a concentration of 4mg/ml limits corneal neovascularization following chemical injury in the male Long–Evans rat model.

Keywords: cornea: basic science • neovascularization 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept